Business Context and Reporting Period
This Form 6-K filing by Autolus Therapeutics Plc covers the month of November 2021, specifically reporting on transactions executed on November 6, 2021, and announced via press release on November 8, 2021. The Company is a biopharmaceutical developer focused on CAR T cell investigational therapy product candidates, primarily obecabtagene autoleucel (obe-cel) for B-cell malignancies.
Key Financial Metrics and Capital Structure
The filing details a significant capital raise and financing arrangement with BXLS V – Autobahn L.P. (Blackstone). The filing text does not provide historical revenue, profit, cash flow, or margin data for the period.
- Total Financing Commitment: Up to $150 million in project financing.
- Upfront Payment: $50 million payable within 15 business days.
- Milestone Payments: Up to $100 million contingent on clinical, manufacturing, and regulatory milestones.
- Equity Investment: $100 million for the purchase of 17,985,611 American Depositary Shares (ADSs) at $5.56 per ADS.
- Warrant Issuance: Warrant to purchase up to 3,265,306 ADSs at an exercise price of $7.35, exercisable until November 6, 2026.
Material Changes and Agreements
The primary material change is the entry into a Collaboration and Financing Agreement with Blackstone. Key terms include:
- Revenue Share: Autolus must pay Blackstone a mid-single digit royalty on net sales of Collaboration Products (obe-cel and next-generation candidates) in B-cell malignancies and certain other indications, subject to an Aggregate Cap.
- Sales Milestones: Additional payments to Blackstone are required if cumulative net sales levels are achieved, also subject to the Aggregate Cap.
- Security Interest: Autolus granted a security interest in its intellectual property, specific cash collateral accounts, and assets related to Collaboration Products to Blackstone. This security remains until cumulative payments equal $150 million or the first U.S. commercial sale of obe-cel occurs.
- Corporate Governance: Blackstone is entitled to appoint a member to Autolus's board of directors and designate a representative to the CMC advisory board.
- Covenants: The agreement includes negative covenants restricting dividends, stock repurchases, and encumbrance of collateral assets until the "Release Time."
Outlook, Risks, and Contingencies
Management commentary is limited to the announcement of the agreement. The filing highlights several risks and contingencies:
- Liquidated Damages: Termination by Blackstone due to certain breaches by the Company could trigger liquidated damage payments exceeding the Blackstone Development Payments.
- Operational Restrictions: The Company is restricted from transferring commercialization rights or assigning royalty rights for Collaboration Products without exceptions.
- Registration Rights: The Company must file a registration statement within 45 days of the closing date (expected by November 12, 2021) to register the shares issued to Blackstone and those underlying the warrant.
Investor Verification Checklist
- Verify the exact definition of the "Aggregate Cap" on royalty and milestone payments in the full Agreement text.
- Confirm the specific clinical, manufacturing, and regulatory milestones required to unlock the remaining $100 million in financing.
- Review the detailed negative covenants to understand restrictions on future capital raising or strategic transactions.
- Monitor the closing of the $100 million equity investment and the subsequent filing of the registration statement for the ADSs.
- Assess the impact of the security interest on Autolus's ability to license or sell its intellectual property related to obe-cel.